Biovail opens new front in Andrx diltiazem dispute

"As a result of preliminary testing to date, Biovail has given notice to Andrx that its Cartia XT product may be infringing the agreed upon dissolution specifications" contained in the Stipulation and Agreement originally signed between Andrx and Aventis. Cartia XT is a generic version of Cardizem CD; Biovail acquired rights to the Aventis brand in January (1"The Pink Sheet" Jan. 8, p. 21). Andrx launched Cartia XT after settling a patent dispute with Aventis; the settlement is the subject of a pending Federal Trade Commission administrative action

More from Archive

More from Pink Sheet